DSIP vs Selank
DSIP directly targets sleep architecture through delta wave induction while Selank addresses anxiety and stress through GABA/serotonin modulation. Both may improve sleep, but through different pathways.
Last updated: 2026-03-08
DSIP (Delta Sleep-Inducing Peptide) and Selank represent two distinct approaches to improving sleep and reducing stress — one targeting sleep architecture directly, the other addressing the anxiety that often underlies sleep problems.
DSIP is a nonapeptide (9 amino acids) first isolated in 1977 from cerebral venous blood of rabbits during induced sleep. It was proposed as an endogenous sleep-promoting factor. Selank is a synthetic heptapeptide analogue of tuftsin, developed at the Institute of Molecular Genetics (Moscow), with anxiolytic and nootropic properties.
While both may improve sleep quality, they do so through fundamentally different mechanisms — making this comparison relevant for researchers investigating sleep and stress management.
**Note:** Neither DSIP nor Selank is approved for clinical use in the UK or EU. Selank has regulatory approval in Russia. This comparison is for educational purposes only.
Quick Comparison Table
| Category | DSIP | Selank |
|---|---|---|
| Peptide Type | Nonapeptide (9 amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) | Heptapeptide (tuftsin analogue with Gly-Pro extension) |
| Primary Effect | Sleep induction and delta wave enhancement | Anxiolytic (anti-anxiety) and nootropic |
| Sleep Mechanism | Direct — promotes slow-wave (delta) sleep | Indirect — reduces anxiety that causes insomnia |
| Administration | Subcutaneous or IV injection | Intranasal spray |
| Regulatory Status | Not approved anywhere | Approved in Russia as anxiolytic |
| Research Quality | Limited, mostly from 1970s-1990s, inconsistent results | Moderate — Russian clinical data plus Western preclinical |
| Side Effects | Minimal reported, but limited data | Well-tolerated; mild nasal irritation, occasional drowsiness |
| Half-Life | Very short (~7-8 minutes); effects outlast presence | Several minutes (intranasal); effects last hours |
Sleep Induction vs Anxiety Reduction
DSIP
DSIP Mechanism — Delta Sleep Induction:
DSIP is proposed to work through multiple sleep-regulatory pathways:
1. **Delta Wave Enhancement:** DSIP increases slow-wave sleep (stages 3-4 / N3) by promoting synchronised delta oscillations in cortical neurons 2. **Somatostatin Interaction:** May modulate somatostatin systems involved in sleep-wake regulation 3. **Stress Hormone Modulation:** Some studies suggest DSIP reduces cortisol and ACTH, potentially creating a more sleep-conducive hormonal environment 4. **Endorphin Interaction:** May interact with opioid systems, potentially promoting relaxation 5. **LH/FSH Effects:** Some research suggests effects on gonadotropin secretion patterns
The Controversy: DSIP research has been plagued by inconsistent results: - Some studies show clear sleep-promoting effects - Others fail to replicate these findings - The peptide is extremely short-lived in blood (~7-8 min half-life) - Yet its sleep effects persist for hours — suggesting it triggers downstream cascades rather than acting directly - The field has largely moved away from the "single sleep factor" model
Current Status: DSIP remains an interesting but incompletely understood peptide. Modern sleep science views sleep regulation as a complex interplay of multiple neurotransmitters and peptides, rather than controlled by a single factor.
Selank
Selank Mechanism — GABAergic Anxiolysis:
Selank is a well-characterised anxiolytic peptide with multiple validated mechanisms:
1. **GABA Enhancement:** Selank increases GABA-A receptor sensitivity, enhancing the brain's primary inhibitory neurotransmitter system 2. **Serotonin Modulation:** Influences serotonin (5-HT) metabolism, stabilising mood and reducing anxiety 3. **BDNF Upregulation:** Increases brain-derived neurotrophic factor, supporting neuroplasticity 4. **Enkephalinase Inhibition:** Stabilises endogenous enkephalins, promoting natural stress resilience 5. **IL-6 Modulation:** Has immunomodulatory effects that may reduce neuroinflammation
How This Improves Sleep: Many people with sleep problems have underlying anxiety: - Racing thoughts prevent sleep onset - Hyperarousal of the stress response keeps the nervous system activated - Cortisol elevation in the evening disrupts natural sleep architecture
By addressing the underlying anxiety, Selank allows natural sleep processes to function: - Reduced sleep onset latency (fall asleep faster) - Less nighttime waking - Improved subjective sleep quality - No next-day sedation or cognitive impairment
Advantage Over Benzodiazepines: Selank provides anxiolysis without: - Sedation - Cognitive impairment - Physical dependence - Tolerance development - Withdrawal symptoms
Clinical Trial Evidence
DSIP Clinical Studies
Participants: Animal (rabbits)
Duration: Acute
Isolated a peptide factor from cerebral venous blood during induced sleep that promoted delta wave sleep when administered to recipient animals.
Original discovery establishing DSIP as a candidate sleep factor.
Participants: 6 patients with chronic insomnia
Duration: 4 nights
DSIP administration improved sleep quality scores and increased slow-wave sleep percentage in 4/6 patients.
Small but suggestive human data. However, very small sample and no control group.
Participants: Review
Duration: N/A
Systematic review found inconsistent results across DSIP studies. Some showed sleep promotion, others found no effect. Methodological concerns noted.
Highlighted the reproducibility problem in DSIP research.
Participants: 97
Duration: 5-7 days
DSIP reduced withdrawal symptoms in opioid-dependent patients, including sleep disturbance, anxiety, and pain.
Interesting alternative application beyond sleep — suggests stress-modulating properties.
Participants: 18
Duration: Single dose
DSIP administration reduced nocturnal cortisol levels and normalised cortisol circadian rhythm in stressed subjects.
Supports the stress hormone modulation mechanism for sleep improvement.
Selank Clinical Studies
Participants: 62 patients with GAD
Duration: 14 days
Selank (intranasal) showed anxiolytic efficacy comparable to medazepam (benzodiazepine) without sedation or cognitive impairment.
Key efficacy study establishing Selank as a benzodiazepine-class anxiolytic without benzodiazepine side effects.
Participants: Animal + in vitro
Duration: Various
Selank enhanced GABA-A receptor binding and modulated serotonin metabolism in the brain. Confirmed dual GABAergic/serotonergic mechanism.
Mechanistic validation of how Selank produces anxiolysis.
Participants: Animal (rat brain)
Duration: Acute
Selank modulated expression of 36 genes involved in GABA and serotonin neurotransmission, inflammation, and neuroplasticity within 1 hour of administration.
Showed rapid and broad gene expression effects supporting multiple beneficial mechanisms.
Participants: Multiple cohorts
Duration: Various
Combined clinical data from regulatory submission studies showed consistent anxiolytic efficacy and excellent tolerability. No dependence, tolerance, or withdrawal.
Led to regulatory approval in Russia as an anxiolytic medication.
Participants: Animal
Duration: 14 days
Combination of Selank and Semax improved cognitive performance in stress-impaired animal models more than either alone.
Supports the popular Selank + Semax nootropic stack and demonstrates complementary mechanisms.
Benefits Comparison
DSIP Unique Benefits
- Directly targets sleep architecture (delta waves)
- May normalise cortisol circadian rhythm
- Historical significance as a sleep research tool
- May have applications in withdrawal management
- Effects persist long after peptide is cleared
Shared Benefits
- May improve sleep quality
- Potential stress hormone reduction
- Short-acting peptides without accumulation
- No significant side effects reported
- May support overall stress resilience
Selank Unique Benefits
- Well-characterised anxiolytic mechanism (GABA + serotonin)
- Regulatory approval in Russia (clinical safety data)
- No sedation, dependence, or tolerance
- Intranasal administration (non-invasive)
- Nootropic benefits alongside anxiolysis
- Better and more consistent research base
- BDNF upregulation for neuroplasticity
Research & Evidence
DSIP Research
DSIP research peaked in the 1980s-1990s and has largely declined. The inconsistent results across studies, very short half-life, and failure of the 'single sleep factor' hypothesis have limited continued investigation. Available human data consists of small, often uncontrolled studies. The peptide remains interesting but under-validated.
Selank Research
Selank has a more robust research base, particularly from Russian clinical studies that led to regulatory approval. Multiple mechanism studies validate the GABA/serotonin pathway. Gene expression studies confirm broad neurobiological effects. While most clinical data comes from Russian sources (limiting Western validation), the consistency and volume of evidence is substantially stronger than DSIP.
Head-to-Head Analysis
No head-to-head studies exist. For sleep improvement specifically, a comparison would need to distinguish direct sleep induction (DSIP) from anxiety-mediated insomnia improvement (Selank) — different patient populations may respond differently to each approach.
Protocol Comparison
DSIP Protocol
DSIP: 100-250 mcg subcutaneous or IV, administered 30-60 minutes before desired sleep time. Research protocols typically run 5-10 days. Due to very short half-life (~7 min), some protocols use multiple low doses. Limited standardisation exists.
Selank Protocol
Selank: 250-500 mcg intranasal (typically 1-3 sprays per nostril), 1-3 times daily. For sleep: evening dose 30-60 minutes before bed. Can be used continuously or in cycles (4 weeks on, 2 weeks off). No tolerance development reported.
Combined Use
DSIP and Selank have not been studied in combination. Theoretically, Selank's anxiolysis could complement DSIP's direct sleep induction. The different administration routes (injection vs intranasal) make combination straightforward. However, both affect overlapping neurotransmitter systems, and interactions are unknown.
Safety Profiles
DSIP Safety
DSIP has limited systematic safety data. Available studies report minimal side effects. The very short half-life suggests limited systemic exposure. Main concerns are the general risks of injection (infection, site reactions) and the lack of comprehensive toxicology data. No serious adverse events have been published.
Selank Safety
Selank has the best safety profile in this comparison, supported by clinical regulatory review. Key safety advantages: no dependence or tolerance, no sedation, no cognitive impairment, no withdrawal effects. Side effects are limited to mild nasal irritation from intranasal administration. The Russian regulatory process, while different from Western standards, includes systematic safety evaluation.
The Verdict: When to Choose Which?
Choose DSIP When:
- When primary issue is difficulty achieving deep sleep (not anxiety-related insomnia)
- When delta wave / slow-wave sleep is the specific research interest
- When exploring the neuroendocrine aspects of sleep regulation
- When comfortable with injectable administration and limited evidence base
Choose Selank When:
- When anxiety or stress is contributing to sleep problems
- When wanting daytime anxiolysis alongside sleep improvement
- When preferring non-invasive administration (intranasal)
- When wanting a compound with regulatory validation
- When nootropic benefits are also desired
- When seeking a well-tolerated, no-dependence option
Consider Combining When:
- Theoretical combination for multi-mechanism sleep support
- DSIP for direct sleep architecture + Selank for anxiety reduction
- No published data on the combination — use with caution
- Consider Selank alone first, as it may be sufficient
Frequently Asked Questions
Conclusion
For most researchers investigating sleep and stress, Selank is the more practical and better-supported choice. Its anxiolytic effects address the most common cause of sleep problems (stress/anxiety), it has regulatory validation, non-invasive administration, and no dependence risk. DSIP remains an interesting research tool for understanding sleep architecture, but its inconsistent clinical results and limited modern research make it less reliable for practical application.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither DSIP nor Selank is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.